| Type | Title | Date Released | |
|---|---|---|---|
10-Q | Form 10-Q | ||
8-K | Niagen Bioscience Reports Third Quarter 2026 Financial Results and Operational Updates | ||
10-Q | Form 10-Q | ||
8-K | Niagen Bioscience Reports Q2 2026 Financial Results and Strategic Expansion into Pharmaceuticals and Telehealth | ||
SCHEDULE 13G | BlackRock, Inc. (Filed by) | ||
424B5 | July 2026 ATM | Offering amount: $50,000,000 | Bank: Canaccord Genuity LLC; Roth Capital Partners, LLC | ||
EFFECT | Form EFFECT | ||
4 | Lopez Carlos Luis (Reporting) | ||
4 | Pamir Ozan (Reporting) | ||
4 | Fried Robert N (Reporting) | ||
8-K | Niagen Bioscience, Inc. Announces Results of 2026 Annual Meeting of Stockholders | ||
S-3 | June 2026 SHELF + ATM |